MCID: EST002
MIFTS: 44

Estrogen-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer 12 15 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060076

Summaries for Estrogen-Receptor Negative Breast Cancer

Disease Ontology : 12 A breast cancer that is characterized by the absence of estrogen receptors.

MalaCards based summary : Estrogen-Receptor Negative Breast Cancer is related to bone resorption disease and estrogen-receptor positive breast cancer. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are PAK Pathway and PI3K-Akt signaling pathway. The drugs Fluorouracil and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, prostate and lymph node, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Related Diseases for Estrogen-Receptor Negative Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 207)
# Related Disease Score Top Affiliating Genes
1 bone resorption disease 30.3 IGF1 ESR1 CYP19A1
2 estrogen-receptor positive breast cancer 29.3 SRC PGR GPER1 FOXA1 ESR1 ERBB2
3 ovarian cancer 28.0 TERT SRC PGR IGF1 GPER1 ESR1
4 breast cancer 27.9 TERT SRC PGR MIR520C IGF1 GPER1
5 bartholin's gland adenoid cystic carcinoma 10.6 PGR ESR1
6 chronic tympanitis 10.6 PGR ESR1
7 bartholin's gland adenoma 10.6 PGR ESR1
8 granulomatous endometritis 10.6 PGR ESR1
9 bartholin's gland benign neoplasm 10.6 PGR ESR1
10 vestibular gland benign neoplasm 10.6 PGR ESR1
11 liver adenomatosis 10.6 PGR AR
12 scirrhous adenocarcinoma 10.6 PGR ERBB2
13 calcifying aponeurotic fibroma 10.6 PGR EGF
14 lung leiomyoma 10.6 PGR ESR1
15 vulvar syringoma 10.6 PGR ESR1
16 trigonitis 10.6 PGR ESR1
17 vagina leiomyosarcoma 10.6 PGR ESR1
18 lipid-rich breast carcinoma 10.6 PGR ERBB2
19 adult type testicular granulosa cell tumor 10.6 PGR ESR1
20 glassy cell carcinoma of the cervix 10.6 PGR ESR1 ERBB2
21 ovarian seromucinous carcinoma 10.6 PGR ESR1
22 breast leiomyoma 10.6 PGR ESR1
23 synchronous bilateral breast carcinoma 10.5 PGR BRCA1
24 breast papillary carcinoma 10.5 PGR ESR1 ERBB2
25 comedo carcinoma 10.5 PGR ESR1 ERBB2
26 lipid-rich carcinoma 10.5 PGR ESR1 ERBB2
27 breast sarcoma 10.5 PGR ESR1 ERBB2
28 apocrine adenosis of breast 10.5 PGR ERBB2
29 breast osteosarcoma 10.5 PGR ESR1 ERBB2
30 familial ovarian cancer 10.5 ESR1 BRCA1
31 cribriform carcinoma 10.5 PGR ESR1 ERBB2
32 intraductal breast neoplasm 10.5 PGR ESR1 ERBB2
33 breast neuroendocrine neoplasm 10.5 PGR ESR1 ERBB2
34 intraductal papilloma 10.5 PGR ESR1 ERBB2
35 adenosarcoma 10.5 PGR ESR1 ERBB2
36 submandibular gland cancer 10.5 ERBB2 AR
37 intravenous leiomyomatosis 10.5 PGR ESR1
38 recurrent respiratory papillomatosis 10.5 ERBB2 EGFR
39 vaginitis 10.5 ESR1 CXCL8 AR
40 endosalpingiosis 10.5 PGR ESR1 BRCA1
41 endometritis 10.5 PGR ESR1 CXCL8
42 liver leiomyoma 10.5 PGR ESR1
43 carcinosarcoma 10.5 PGR ERBB2 EGFR
44 serous cystadenocarcinoma 10.5 PGR ERBB2 BRCA1
45 breast adenoid cystic carcinoma 10.5 PGR ERBB2
46 breast mucinous carcinoma 10.5 PGR ERBB2
47 benign metastasizing leiomyoma 10.4 PGR CYP19A1
48 oncocytic breast carcinoma 10.4 PGR ESR1 ERBB2 AR
49 juvenile nasopharyngeal angiofibroma 10.4 PGR ESR1 CYP19A1
50 vulvar disease 10.4 PGR ERBB2 EGFR

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:



Diseases related to Estrogen-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.43 EGFR ERBB2 IGF1 SRC
2 Decreased viability with paclitaxel GR00179-A-2 9.43 IGF1
3 Decreased viability with paclitaxel GR00179-A-3 9.43 EGFR
4 Increased cell death HMECs cells GR00103-A-0 9.1 AHR BRCA1 EGFR GPER1 PGR PTPRA

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 AHR AR BRCA1 CLDN12 CYP19A1 EGF
2 endocrine/exocrine gland MP:0005379 10.41 AHR AR BRCA1 CYP19A1 EGF EGFR
3 immune system MP:0005387 10.4 AHR AR BRCA1 CLDN12 CLPTM1L CYP19A1
4 homeostasis/metabolism MP:0005376 10.38 AHR AR BRCA1 CLDN12 CYP19A1 EGFR
5 cellular MP:0005384 10.36 AHR AR BRCA1 CYP19A1 EGFR ERBB2
6 hematopoietic system MP:0005397 10.36 AHR AR BRCA1 CLDN12 CLPTM1L CYP19A1
7 cardiovascular system MP:0005385 10.33 AHR AR BRCA1 CLDN12 CYP19A1 EGFR
8 integument MP:0010771 10.29 AHR AR BRCA1 CYP19A1 EGF EGFR
9 digestive/alimentary MP:0005381 10.27 AHR AR BRCA1 CYP19A1 EGF EGFR
10 mortality/aging MP:0010768 10.27 AHR AR BRCA1 CLDN12 CLPTM1L EGFR
11 nervous system MP:0003631 10.18 AHR AR BRCA1 CLDN12 CLPTM1L CYP19A1
12 limbs/digits/tail MP:0005371 10.15 AR BRCA1 EGFR ERBB2 ESR1 GPER1
13 adipose tissue MP:0005375 10.14 AR BRCA1 CLDN12 CYP19A1 EGFR ESR1
14 neoplasm MP:0002006 10.14 AHR AR BRCA1 EGFR ERBB2 ESR1
15 muscle MP:0005369 10.13 AHR AR BRCA1 CLDN12 CYP19A1 EGFR
16 liver/biliary system MP:0005370 10.08 AHR AR CLDN12 CYP19A1 EGFR ESR1
17 normal MP:0002873 10.02 AR BRCA1 CYP19A1 EGF EGFR ERBB2
18 reproductive system MP:0005389 9.97 AHR AR BRCA1 CYP19A1 EGF EGFR
19 pigmentation MP:0001186 9.65 AR BRCA1 CYP19A1 EGFR SRC
20 respiratory system MP:0005388 9.56 AHR BRCA1 EGFR ERBB2 ESR1 IGF1
21 skeleton MP:0005390 9.44 AHR AR BRCA1 CLDN12 CYP19A1 EGFR

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3 51-21-8 3385
2
Epirubicin Approved Phase 3 56420-45-2 41867
3
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
5
leucovorin Approved Phase 3 58-05-9 6006 143
6
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
7
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
8
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
9
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
10
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
11
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
12
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
13
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
14
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Lapatinib Approved, Investigational Phase 3 231277-92-2, 388082-78-8 208908 9941095
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18 Folic Acid Antagonists Phase 3
19 Dermatologic Agents Phase 3
20 Folate Phase 3
21 Vitamin B9 Phase 3
22 Antimetabolites Phase 3
23 Vitamin B Complex Phase 3
24 Anti-Infective Agents Phase 2, Phase 3
25 Antiviral Agents Phase 2, Phase 3
26 Protein Kinase Inhibitors Phase 3
27 Estrogens Phase 3
28 Hormones Phase 3
29 Hormone Antagonists Phase 3
30 Progestins Phase 3
31 Immunologic Factors Phase 3
32 Alkylating Agents Phase 3
33 Immunosuppressive Agents Phase 3
34 Antirheumatic Agents Phase 3
35 Albumin-Bound Paclitaxel Phase 3
36 Antimitotic Agents Phase 3
37 Anti-Bacterial Agents Phase 3
38 Topoisomerase Inhibitors Phase 3
39 Antibiotics, Antitubercular Phase 3
40
Liposomal doxorubicin Phase 3 31703
41 Antineoplastic Agents, Immunological Phase 3
42 Triamcinolone diacetate Phase 3
43 Triamcinolone hexacetonide Phase 3
44 triamcinolone acetonide Phase 3
45
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
46
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
47
Bevacizumab Approved, Investigational Phase 2 216974-75-3
48
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
49
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
50
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
2 Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
3 Low-dose Cytotoxics as "Anti-angiogenesis Treatment" Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer Completed NCT00022516 Phase 3 Cyclophosphamide;Methotrexate
4 A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer Completed NCT01881230 Phase 2, Phase 3 nab-Paclitaxel;Carboplatin;Gemcitabine
5 Ovarian Protection Trial In Premenopausal Breast Cancer Patients [OPTION] Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
6 A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
7 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer Recruiting NCT01805076 Phase 3
8 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
9 Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
10 A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer Active, not recruiting NCT01349322 Phase 3
11 Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study - Biological Phase (EPHOS-B) Active, not recruiting NCT01104571 Phase 3 lapatinib ditosylate
12 Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer Completed NCT00239343 Phase 2 gefitinib
13 A Phase II Study of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced Breast Cancer Completed NCT00559507 Phase 2 saracatinib
14 MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial Completed NCT00577122 Phase 2 Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
15 Multicenter Pilot Clinical Study of Adjuvant Chemotherapy for Subjects Over 70 Years: Impact on the Independence and Quality of Life of the Administration of Anthracycline-Based Chemotherapy in Adjuvant Setting for Patients Presenting With Immediately Operable Breast Cancer, Hormone Receptor Negative (RH-), and Lymph Node Positive (pN+) or pN0 But of Scarff-Bloom-Richardson* Grade III and ≥ 2cm [GERICO] Completed NCT00424203 Phase 2 AC regimen;cyclophosphamide;doxorubicin hydrochloride
16 NEO-ADIXERN (NEO-ADjuvant IXabepilone in Breast Cancer). A Feasibility Study of Dose-dense FEC With G-CSF Support Followed by Dose-dense Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in Breast Cancer Completed NCT00751868 Phase 2 Ixabepilone
17 Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib Completed NCT00733408 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
18 A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer Completed NCT00056082 Phase 2 celecoxib
19 An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer Completed NCT01818063 Phase 2 Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
20 Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer Completed NCT00834678 Phase 1, Phase 2 bendamustine;erlotinib;Maintenance erlotinib
21 A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
22 Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer Completed NCT01105312 Phase 1, Phase 2 letrozole;panobinostat
23 A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
24 A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A)and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy For Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
25 A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC) Recruiting NCT02315196 Phase 2 pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
26 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer Active, not recruiting NCT01471106 Phase 2 Dasatinib
27 Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Active, not recruiting NCT01372579 Phase 2 eribulin mesylate;carboplatin
28 A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers Active, not recruiting NCT01147016 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
29 A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma Terminated NCT01151449 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
30 A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer Terminated NCT01918306 Phase 1, Phase 2 cisplatin;GDC -0941
31 GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response Terminated NCT01234532 Phase 2 entinostat;anastrozole
32 A Pilot Study of BR-DIM in Women With Stage II-III, Triple Negative, and Androgen Receptor Positive, Invasive Breast Cancer, Who Have Residual Disease Following Surgical Resection After Neoadjuvant Chemotherapy Withdrawn NCT01612910 Phase 2 oral microencapsulated diindolylmethane
33 Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer Completed NCT01104259 Phase 1 veliparib;cisplatin;vinorelbine tartrate
34 Phase I Clinical Trial of Trametes Versicolor in Women With Breast Cancer Completed NCT00680667 Phase 1
35 Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
36 Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative Terminated NCT01217411 Phase 1 Gamma-secretase/Notch signalling pathway inhibitor RO4929097
37 Colon and Breast Cancer Diagnostics. Clinical Protocol Associated With Cancer of the Breast. Unknown status NCT00897728
38 Change in Mammographic Density With Metformin Use: A Companion Study to NCIC Study MA.32 Unknown status NCT01666171 metformin hydrochloride
39 Modifications of Hormone Receptors and Biological Parameters of Metastatic Breast Cancer Treated With First-line Chemotherapy. Prospective Biological Study. Completed NCT00870168 chemotherapy
40 A Randomized Trial Of Axillary Dissection Versus No Axillary Dissection For Patients With Clinically Node Negative Breast Cancer And Micrometastases In The Sentinel Node Completed NCT00072293
41 Effects of Chemotherapy on Brain Structure and Function Completed NCT00755313 aromatase inhibition therapy;carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride
42 Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer Completed NCT00068328
43 Pilot Evaluation of Bevacizumab, in Combination With Docetaxel and Cyclophosphamide in the Adjuvant Treatment of Patients With HER 2 Negative Breast Cancer Completed NCT00911716 cyclophosphamide;docetaxel
44 Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer With 0-3 Positive Axillary Lymph Nodes Completed NCT00115505
45 Assessment of Candidate Protein Expression in Human Breast Cancer Specimens Recruiting NCT00918892
46 A Pilot Study of the Effect of Erlotinib (Tarceva®) on Biomarkers in Estrogen Receptor Negative Breast Cancer Expressing the Epidermal Growth Factor Receptor and Interleukin 1α Terminated NCT00503841 erlotinib hydrochloride

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

40
Breast, Prostate, Lymph Node, Colon, Lung, Bone, Brain

Publications for Estrogen-Receptor Negative Breast Cancer

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 314)
# Title Authors PMID Year
1
G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer. 61
32034133 2020
2
High expression of soluble CD155 in estrogen receptor-negative breast cancer. 61
31372841 2020
3
Cytotoxic, anti-proliferative and apoptotic effects of noscapine on human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines. 61
31950839 2020
4
miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. 61
31875548 2019
5
GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. 61
31694641 2019
6
Galbanic acid: Induced antiproliferation in estrogen receptor-negative breast cancer cells and enhanced cellular redox state in the human dermal fibroblasts. 61
31576639 2019
7
Breast cancer subtypes among Eastern-African-born black women and other black women in the United States. 61
31190337 2019
8
β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. 61
31290053 2019
9
Bioinformatics analysis identifies potential chemoresistance-associated genes across multiple types of cancer. 61
31402953 2019
10
Corrigendum to ``Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells'' [Phytomedicine 22(9) (2015) 820-828]. 61
31272032 2019
11
AKT-dependent sugar addiction by benzyl isothiocyanate in breast cancer cells. 61
30720225 2019
12
Increased expression of mitochondrial sodium-coupled ascorbic acid transporter-2 (mitSVCT2) as a central feature in breast cancer. 61
30902760 2019
13
Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor. 61
30936413 2019
14
Oleuropein induces apoptosis via abrogating NF-κB activation cascade in estrogen receptor-negative breast cancer cells. 61
30260018 2019
15
Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model. 61
29133279 2019
16
Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling. 61
30792401 2019
17
Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROS‑mediated PI3K/AKT signaling pathway. 61
30483797 2019
18
LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors. 61
30575334 2019
19
Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2. 61
30617282 2019
20
RASAL2 Plays Inconsistent Roles in Different Cancers. 61
31799194 2019
21
[Effect of serum containing Xihuang pill on proliferation of human breast cancer cell line MDA-MB-435 and MCF-7 Cells]. 61
30111032 2018
22
Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data. 61
29518546 2018
23
Cellular and Animal Model Studies on the Growth Inhibitory Effects of Polyamine Analogues on Breast Cancer. 61
29533973 2018
24
Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies. 61
29455641 2018
25
Associations between Diet Quality Scores and Risk of Postmenopausal Estrogen Receptor-Negative Breast Cancer: A Systematic Review. 61
29378048 2018
26
The A2B adenosine receptor in MDA-MB-231 breast cancer cells diminishes ERK1/2 phosphorylation by activation of MAPK-phosphatase-1. 61
30157211 2018
27
Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment. 61
29246124 2017
28
Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. 61
29087320 2017
29
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. 61
29058716 2017
30
Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention. 61
28912152 2017
31
Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. 61
28877935 2017
32
Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women. 61
29141994 2017
33
Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. 61
28886987 2017
34
New semi-synthetic analogs of oleuropein show improved anticancer activity in vitro and in vivo. 61
28551177 2017
35
Immunocytochemical stem cell markers can predict clinical stage of breast cancer. 61
28714035 2017
36
Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. 61
28957356 2017
37
PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer. 61
28881566 2017
38
Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. 61
28263391 2017
39
AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. 61
28238761 2017
40
Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer. 61
29069648 2017
41
WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. 61
28469783 2017
42
Long-Term Sleep Duration as a Risk Factor for Breast Cancer: Evidence from a Systematic Review and Dose-Response Meta-Analysis. 61
29130041 2017
43
FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer. 61
28028927 2017
44
Jim Crow and estrogen-receptor-negative breast cancer: US-born black and white non-Hispanic women, 1992-2012. 61
27988896 2017
45
Toll-like receptor 4 as a predictor of clinical outcomes of estrogen receptor-negative breast cancer in Saudi women. 61
28280355 2017
46
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. 61
28039445 2017
47
Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. 61
27935862 2017
48
Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer. 61
27431462 2016
49
Pharmacological evaluation of poly(3-methylthiophene) and its titanium(IV)phosphate nanocomposite: DNA interaction, molecular docking, and cytotoxic activity. 61
27710872 2016
50
Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer. 61
26926102 2016

Variations for Estrogen-Receptor Negative Breast Cancer

Expression for Estrogen-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.

Pathways for Estrogen-Receptor Negative Breast Cancer

Pathways related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.31 SRC PTPRA IGF1 ERBB2 EGFR EGF
2
Show member pathways
12.99 TERT IGF1 ERBB2 EGFR EGF BRCA1
3
Show member pathways
12.85 SRC IGF1 ERBB2 EGFR EGF AR
4 12.7 TERT IGF1 ESR1 ERBB2 EGFR EGF
5
Show member pathways
12.62 SRC IGF1 ERBB2 EGFR EGF
6
Show member pathways
12.6 SRC PGR IGF1 GPER1 ESR1 EGFR
7
Show member pathways
12.51 SRC ERBB2 EGFR EGF
8
Show member pathways
12.4 SRC IGF1 ERBB2 EGFR EGF
9
Show member pathways
12.29 SRC ERBB2 EGFR EGF
10
Show member pathways
12.27 IGF1 ESR1 ERBB2 EGFR EGF
11 12.24 SRC IGF1 ESR1 ERBB2 EGFR
12
Show member pathways
12.22 TERT PGR IGF1 ESR1 ERBB2 EGFR
13 12.19 SRC ERBB2 EGFR EGF
14
Show member pathways
12.13 SRC ERBB2 EGFR EGF
15 12.12 SRC ERBB2 EGFR EGF
16 12.05 TERT IGF1 FOXA1 EGF
17 11.94 SRC IGF1 EGFR EGF
18 11.92 IGF1 ERBB2 EGFR EGF
19 11.92 ESR1 EGFR CYP19A1 BRCA1 AR AHR
20 11.9 SRC PTPRA EGFR EGF
21
Show member pathways
11.86 ESR1 ERBB2 EGFR
22
Show member pathways
11.86 SRC EGFR EGF
23
Show member pathways
11.84 PGR ESR1 AR
24
Show member pathways
11.84 PGR ESR1 ERBB2 EGFR EGF
25 11.83 SRC EGFR EGF
26 11.82 SRC EGFR BRCA1 AR
27
Show member pathways
11.82 SRC IGF1 GPER1 ESR1 ERBB2 EGFR
28
Show member pathways
11.8 SRC IGF1 ERBB2 EGFR EGF AR
29 11.78 TERT CXCL8 AR
30
Show member pathways
11.77 SRC EGFR EGF
31 11.73 SRC ERBB2 EGFR
32 11.71 SRC ERBB2 EGFR
33 11.68 SRC EGFR CXCL8
34 11.65 IGF1 EGFR CXCL8
35 11.62 SRC ERBB2 EGFR
36 11.62 TERT ESR1 EGFR EGF
37
Show member pathways
11.6 SRC ERBB2 EGFR EGF
38 11.58 TERT IGF1 EGF CXCL8
39 11.58 SRC ERBB2 EGFR EGF CXCL8
40 11.55 SRC EGFR EGF
41 11.53 SRC EGFR AHR
42 11.5 IGF1 CYP19A1 AR
43 11.49 SRC EGFR EGF
44 11.49 SRC ERBB2 EGFR
45
Show member pathways
11.44 SRC EGFR EGF
46 11.44 SRC ESR1 EGFR AHR
47
Show member pathways
11.4 FOXA1 ESR1 BRCA1 AR
48 11.32 SRC EGFR EGF
49 11.32 SRC EGFR EGF
50 11.27 ERBB2 EGFR EGF

GO Terms for Estrogen-Receptor Negative Breast Cancer

Cellular components related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.92 PTPRA ERBB2 EGFR EGF

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.19 SRC PGR IGF1 GPER1 ESR1 ERBB2
2 regulation of transcription by RNA polymerase II GO:0006357 10.1 FOXA1 ESR1 ERBB2 EGFR BRCA1 AR
3 positive regulation of cell proliferation GO:0008284 10.05 IGF1 GPER1 ERBB2 EGFR EGF AR
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 PGR IGF1 GPER1 FOXA1 ESR1 EGFR
5 MAPK cascade GO:0000165 9.96 PTPRA ERBB2 EGFR EGF
6 positive regulation of cell migration GO:0030335 9.96 IGF1 GPER1 EGFR EGF
7 regulation of gene expression GO:0010468 9.96 IGF1 FOXA1 AR AHR
8 cell proliferation GO:0008283 9.95 SRC IGF1 EGFR AR
9 negative regulation of gene expression GO:0010629 9.95 TERT PGR IGF1 GPER1 ESR1
10 peptidyl-tyrosine phosphorylation GO:0018108 9.91 SRC ERBB2 EGFR EGF
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 SRC IGF1 GPER1
12 positive regulation of MAPK cascade GO:0043410 9.83 IGF1 GPER1 ERBB2 AR
13 positive regulation of protein kinase B signaling GO:0051897 9.83 SRC ESR1 ERBB2 EGFR EGF
14 positive regulation of epithelial cell proliferation GO:0050679 9.82 IGF1 ERBB2 EGFR
15 positive regulation of fibroblast proliferation GO:0048146 9.8 IGF1 ESR1 EGFR
16 positive regulation of gene expression GO:0010628 9.8 SRC IGF1 GPER1 ERBB2 EGF BRCA1
17 epidermal growth factor receptor signaling pathway GO:0007173 9.79 SRC EGFR EGF
18 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.77 SRC IGF1 AR
19 intracellular receptor signaling pathway GO:0030522 9.77 ESR1 AR AHR
20 cellular response to estradiol stimulus GO:0071392 9.76 GPER1 ESR1 EGFR
21 regulation of cell motility GO:2000145 9.71 ERBB2 EGFR EGF
22 positive regulation of MAP kinase activity GO:0043406 9.71 SRC ERBB2 EGFR EGF
23 positive regulation of phosphorylation GO:0042327 9.69 EGFR EGF AR
24 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.67 IGF1 AR
25 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.67 FOXA1 AR
26 steroid hormone mediated signaling pathway GO:0043401 9.67 PGR GPER1 ESR1 AR
27 progesterone receptor signaling pathway GO:0050847 9.65 SRC PGR
28 uterus development GO:0060065 9.65 SRC ESR1 CYP19A1
29 prostate gland epithelium morphogenesis GO:0060740 9.64 FOXA1 AR
30 prostate gland growth GO:0060736 9.63 CYP19A1 AR
31 intracellular steroid hormone receptor signaling pathway GO:0030518 9.63 GPER1 ESR1
32 mammary gland alveolus development GO:0060749 9.63 ESR1 EGF AR
33 morphogenesis of an epithelial fold GO:0060571 9.61 EGFR AR
34 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.57 PGR AR
35 positive regulation of transcription, DNA-templated GO:0045893 9.56 SRC IGF1 ESR1 EGFR EGF BRCA1
36 negative regulation of ERBB signaling pathway GO:1901185 9.33 ERBB2 EGFR EGF
37 ERBB2 signaling pathway GO:0038128 8.92 SRC ERBB2 EGFR EGF

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.98 TERT PGR ESR1 ERBB2 EGFR CLDN12
2 chromatin binding GO:0003682 9.85 GPER1 FOXA1 ESR1 EGFR AR
3 transcription regulatory region DNA binding GO:0044212 9.8 FOXA1 BRCA1 AR AHR
4 enzyme binding GO:0019899 9.73 SRC PGR ESR1 EGFR BRCA1 AR
5 ATPase binding GO:0051117 9.65 PGR ESR1 AR
6 transcription coactivator binding GO:0001223 9.5 TERT ESR1 AHR
7 steroid hormone receptor activity GO:0003707 9.46 PGR GPER1 ESR1 AR
8 nitric-oxide synthase regulator activity GO:0030235 9.4 ESR1 EGFR
9 estrogen receptor activity GO:0030284 9.37 GPER1 ESR1
10 nuclear receptor activity GO:0004879 9.26 PGR ESR1 AR AHR
11 steroid binding GO:0005496 8.92 PGR GPER1 ESR1 AR

Sources for Estrogen-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....